CTIC · Cti Biopharma Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.12M | - | $0 | $0 | $0 | - | - | - | - | - |
| Cost of Revenue | $1.22M | - | $0 | $0 | $278.0K | - | - | - | - | - |
| Gross Profit | $22.89M | - | $0 | $0 | ($278.0K) | - | - | - | - | - |
| R&D | $10.21M | - | $8.22M | $8.71M | $8.05M | - | $9.72M | $9.29M | $9.44M | - |
| SG&A | $21.91M | - | $21.50M | $21.59M | $18.05M | - | $13.66M | $10.21M | $7.63M | - |
| Total Operating Expenses | $33.35M | - | $30.46M | $31.21M | $37.40M | - | $23.38M | $19.51M | $17.07M | - |
| D&A | $520.0K | - | - | - | $317.0K | - | - | - | $135.0K | - |
| Operating Income | ($9.23M) | - | ($12.22M) | ($18.88M) | ($35.10M) | - | ($23.38M) | ($19.51M) | ($17.07M) | - |
| Interest Expense | $4.18M | - | $3.56M | $3.76M | $2.06M | - | $531.0K | $45.0K | $68.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($13.42M) | - | ($15.71M) | ($22.65M) | ($37.17M) | - | ($24.18M) | ($19.68M) | ($17.27M) | - |
| EPS - Basic | ($0.10) | - | ($0.13) | ($0.21) | ($0.37) | - | ($0.26) | ($0.19) | - | - |
| EPS - Diluted | ($0.10) | - | ($0.13) | ($0.21) | ($0.23) | - | ($0.26) | ($0.19) | - | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.21M | $30.42M | $32.05M | $66.09M | $96.90M | $65.45M | $95.28M | $71.88M | $33.10M | $40.39M |
| Accounts Receivable | $22.96M | $15.39M | $10.59M | $8.16M | $2.43M | - | - | - | - | - |
| Inventory | $777.0K | $733.0K | $1.15M | $702.0K | $0 | - | - | - | - | - |
| Accounts Payable | $2.02M | $2.01M | $2.44M | $3.10M | $2.42M | $3.89M | $1.78M | $1.29M | $1.17M | $1.64M |
| Current Assets | $86.45M | $99.40M | $96.94M | $107.37M | $103.28M | $68.38M | $99.05M | $74.82M | $39.35M | $54.33M |
| Total Assets | $112.27M | $125.92M | $123.47M | $134.53M | $131.44M | $72.43M | $101.23M | $77.50M | $42.79M | $58.24M |
| Current Liabilities | $68.23M | $81.13M | $29.77M | $29.79M | $98.93M | $66.65M | $62.34M | $15.79M | $15.56M | $17.04M |
| Long-term Debt | - | $47.94M | $47.80M | $47.66M | - | $47.38M | - | - | - | $0 |
| Total Liabilities | $137.62M | $143.50M | $140.30M | $139.81M | $159.35M | $68.67M | $62.34M | $15.79M | $16.14M | $18.21M |
| Stockholders' Equity | ($25.35M) | ($17.58M) | ($16.84M) | ($5.27M) | $3.77M | $3.77M | $38.89M | $61.71M | $26.65M | $40.03M |
| Retained Earnings | ($2.53B) | ($2.52B) | ($2.50B) | ($2.49B) | ($2.46B) | ($2.43B) | ($2.39B) | ($2.36B) | ($2.35B) | ($2.33B) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($31.10M) | - | - | - | ($29.98M) | - | - | - | ($16.78M) | - |
| Investing Cash Flow | $15.26M | - | - | - | $0 | - | - | - | $8.00M | - |
| Financing Cash Flow | $9.63M | - | - | - | $61.43M | - | - | - | $1.49M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 94.9% | - | - | - | - | - | - | - | - | - |
| Operating margin | -38.3% | - | - | - | - | - | - | - | - | - |
| EBITDA margin | -36.1% | - | - | - | - | - | - | - | - | - |
| Net margin | -55.7% | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 42.3% | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 90.9% | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.0% | - | -12.7% | -16.8% | -28.3% | - | -23.9% | -25.4% | -40.4% | - |
| Return on equity | 53.0% | - | 93.3% | 429.5% | -986.9% | - | -62.2% | -31.9% | -64.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.27 | 1.23 | 3.26 | 3.60 | 1.04 | 1.03 | 1.59 | 4.74 | 2.53 | 3.19 |
| Quick ratio | 1.26 | 1.22 | 3.22 | 3.58 | 1.04 | 1.03 | 1.59 | 4.74 | 2.53 | 3.19 |
| Cash ratio | 0.35 | 0.37 | 1.08 | 2.22 | 0.98 | 0.98 | 1.53 | 4.55 | 2.13 | 2.37 |
| Leverage | ||||||||||
| Debt / Equity | - | -2.73 | -2.84 | -9.04 | - | 12.58 | - | - | - | 0.00 |
| Debt / Assets | - | 0.38 | 0.39 | 0.35 | - | 0.65 | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -2.2x | - | -3.4x | -5.0x | -17.0x | - | -44.0x | -433.5x | -251.0x | - |
| Equity multiplier | -4.43 | -7.16 | -7.33 | -25.51 | 34.89 | 19.23 | 2.60 | 1.26 | 1.61 | 1.45 |
| Liabilities / Assets | 1.23 | 1.14 | 1.14 | 1.04 | 1.21 | 0.95 | 0.62 | 0.20 | 0.38 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | 0.21 | - | 0.00 | 0.00 | 0.00 | - | - | - | - | - |
| Inventory turnover | 1.58 | - | 0.00 | 0.00 | - | - | - | - | - | - |
| Days sales outstanding | 347d | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 232d | - | - | - | 0d | - | - | - | - | - |
| Days payable outstanding | 604d | - | - | - | 3184d | - | - | - | - | - |
| Cash conversion cycle | -25d | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | 18.1% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 73.7% | - | 47.7% | 3.2% | -105.6% | - | -111.7% | -95.1% | -43.1% | - |
| Net income growth (YoY) | 63.9% | - | 35.0% | -15.1% | -115.3% | - | -114.7% | -40.5% | -41.7% | - |
| EPS growth (YoY) | 56.5% | - | 50.0% | -10.5% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | -85.9% | -90.6% | -16.9% | 8.5% | -5.3% | 69.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CTI BIOPHARMA CORP against the 5 most active filers in the same SIC group.